Randomized Trialhigh evidence
Earlier Disclosure of Blood-Based Biomarkers, Diagnostic Certainty, and Clinical Management: A Randomized Clinical Trial.
JAMA neurology·October 5, 2026·PMID 42832237
Why it mattersDiagnostic uncertainty in cognitive disorders often delays targeted management and burdens memory clinics with repeated assessments. This trial shows that earlier disclosure of blood-based biomarkers can rapidly increase diagnostic confidence and streamline care, potentially improving patient flow and enabling earlier treatment decisions.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled